Lincoln Pharmaceuticals Limited has informed the Exchange regarding Change in Director(s) of the company.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lincoln Pharmaceuticals has received board approval to re-appoint four directors, subject to shareholder approval at the upcoming AGM. Mr. Mahendra G. Patel (promoter, 45+ years of pharma experience) will continue as Managing Director for 5 years from October 1, 2025 to September 30, 2030. Mr. Hashmukh I. Patel will be re-appointed as Whole Time Director for the same 5-year period. Mr. Ashish R. Patel (son of Mr. Rajnikant G. Patel) and Mr. Munjal M. Patel (son of Mahendra G. Patel) will each be re-appointed as Whole Time Directors for 5 years from November 14, 2025 to November 13, 2030. All four are existing directors being re-appointed, and none are debarred by SEBI from holding directorship.
This is a routine continuity announcement with no change in leadership or board composition. Existing management, including the promoter family, continues for another five-year cycle, which is neutral for shareholders and unlikely to move the stock.